Biomarkers Assessing Endothelial Dysfunction in Alzheimer's Disease.

Area of Science:

• Neuroscience
• Vascular Biology
• Gerontology

Background:

• Alzheimer's disease (AD) is a leading cause of dementia in the elderly.
• Endothelial dysfunction is increasingly recognized as a critical factor in AD pathogenesis.
• Vascular risk factors contribute to blood-brain barrier (BBB) compromise in AD.

Purpose of the Study:

• To explore the role of endothelial dysfunction in Alzheimer's disease.
• To identify early biomarkers for endothelial dysfunction in AD.
• To investigate potential therapeutic targets for AD based on endothelial dysfunction.

Main Methods:

• Review of current evidence linking endothelial dysfunction and AD.
• Analysis of biomarker changes associated with BBB disruption.
• Exploration of neuroinflammatory and neurodegenerative pathways.

Main Results:

• Endothelial dysfunction compromises the BBB, allowing toxic substances into the brain.
• Increased adhesion molecules and endothelin-1 indicate vascular inflammation and BBB permeability.
• Neuroinflammation and astrogliosis result from BBB disruption, leading to neuronal degeneration.

Conclusions:

• Endothelial dysfunction is a significant contributor to cognitive decline in Alzheimer's disease.
• Biomarkers of endothelial dysfunction could serve as early diagnostic and prognostic markers for AD.
• Identifying these biomarkers opens avenues for new therapeutic strategies against AD.